A Phase 1/2 Safety Study of Intratumorally Dosed INT230-6
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Breast Cancer|Head and Neck Cancer|Squamous Cell Carcinoma|Lymphoma|Pancreatic Cancer|Liver Cancer|Colon Cancer|Lung Cancer|Bile Duct Cancer|Chordoma of Sacrum|Sarcoma
Interventions: DRUG: INT230-6|BIOLOGICAL: anti-PD-1 antibody|BIOLOGICAL: anti-CTLA-4 antibody
Sponsor: Intensity Therapeutics, Inc.
Collaborators: Merck Sharp & Dohme LLC|Bristol-Myers Squibb